Lower hsCRP was associated with lower cardiovascular risk, but this secondary analysis cannot prove that reducing inflammation caused the benefit; hsCRP is a marker, not proof of a treatment mechanism ([limitations](doi.org/10.1161/CIRC...)). (3/4)
October 5, 2026 at 3:06 PM
Lower hsCRP was associated with lower cardiovascular risk, but this secondary analysis cannot prove that reducing inflammation caused the benefit; hsCRP is a marker, not proof of a treatment mechanism ([limitations](doi.org/10.1161/CIRC...)). (3/4)
At 104 weeks, semaglutide lowered hsCRP by 37.8% versus placebo ([full study](doi.org/10.1161/CIRC...)). (2/4)
October 5, 2026 at 3:05 PM
At 104 weeks, semaglutide lowered hsCRP by 37.8% versus placebo ([full study](doi.org/10.1161/CIRC...)). (2/4)
Residents of the greened neighborhoods experienced 13 to 20 percent lower levels of hsCRP, a blood marker of inflammation that is associated with cardiovascular disease risk and is a strong predictor of heart attacks.
October 5, 2026 at 8:06 PM
Residents of the greened neighborhoods experienced 13 to 20 percent lower levels of hsCRP, a blood marker of inflammation that is associated with cardiovascular disease risk and is a strong predictor of heart attacks.
Semaglutide in T2D: a bone marrow effect? (n=16, before–after, 6 months)
- CD16+ monocytes −18.8% (P=.034)
- Bone marrow 68Ga-DOTATATE uptake −17.5% (P=.037)
- hsCRP −1.0 mg/L
- No reduction in coronary or spleen uptake
Hypothesis-generating.
doi.org/10.1093/eurh...
- CD16+ monocytes −18.8% (P=.034)
- Bone marrow 68Ga-DOTATATE uptake −17.5% (P=.037)
- hsCRP −1.0 mg/L
- No reduction in coronary or spleen uptake
Hypothesis-generating.
doi.org/10.1093/eurh...
Potential bone marrow–driven reduction of circulating inflammatory monocytes by semaglutide in Type 2 diabetes
AbstractBackground and Aims. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) reduce cardiovascular disease (CVD) in type 2 diabetes (T2D) and have ant
doi.org
October 2, 2026 at 9:47 AM
Semaglutide in T2D: a bone marrow effect? (n=16, before–after, 6 months)
- CD16+ monocytes −18.8% (P=.034)
- Bone marrow 68Ga-DOTATATE uptake −17.5% (P=.037)
- hsCRP −1.0 mg/L
- No reduction in coronary or spleen uptake
Hypothesis-generating.
doi.org/10.1093/eurh...
- CD16+ monocytes −18.8% (P=.034)
- Bone marrow 68Ga-DOTATATE uptake −17.5% (P=.037)
- hsCRP −1.0 mg/L
- No reduction in coronary or spleen uptake
Hypothesis-generating.
doi.org/10.1093/eurh...
＜（ドクター用）「炎症」が動脈硬化性心血管疾患（ASCVD）の因果的な役割を果たしている＞ 炎症説を支持するエビデンスは多岐にわたる。病理組織標本ではプラーク内に炎症細胞が認められており、観察研究では炎症性バイオマーカーである高感度C反応性蛋白（hsCRP）の血清レベルと心イベントとの相関が示され、遺伝学的研究では、インターロイキン-6（IL-6）の阻害を模倣するIL-6受容体の変異体が、ASCVDリスクの低下を予測することが観察されている。
September 30, 2026 at 3:05 PM
＜（ドクター用）「炎症」が動脈硬化性心血管疾患（ASCVD）の因果的な役割を果たしている＞ 炎症説を支持するエビデンスは多岐にわたる。病理組織標本ではプラーク内に炎症細胞が認められており、観察研究では炎症性バイオマーカーである高感度C反応性蛋白（hsCRP）の血清レベルと心イベントとの相関が示され、遺伝学的研究では、インターロイキン-6（IL-6）の阻害を模倣するIL-6受容体の変異体が、ASCVDリスクの低下を予測することが観察されている。
Human protocols in trials used 5-16mg oral daily for 3-12 months. UK users often track lymphocyte telomere length and hsCRP, but changes do not automatically equal functional gains.
September 22, 2026 at 5:01 PM
Human protocols in trials used 5-16mg oral daily for 3-12 months. UK users often track lymphocyte telomere length and hsCRP, but changes do not automatically equal functional gains.
One post-MI RCT at 16mg daily for 12 months increased lymphocytes by 285 cells/μl and cut hsCRP 62%. Yet pooled data across trials showed no consistent improvement in frailty or broad inflammation markers.
September 22, 2026 at 5:01 PM
One post-MI RCT at 16mg daily for 12 months increased lymphocytes by 285 cells/μl and cut hsCRP 62%. Yet pooled data across trials showed no consistent improvement in frailty or broad inflammation markers.
CLOAK study: 3 mos DBRPCT of Colchicine vs PBO (no NSAID) in 120 symptomatic KOA (KL gr 2/3) shows no benefit in VAS pain index knee after 3 mos. (but COL pts had signif change in some biomarkers hsCRP, β-NGF (p < 0.05); PGE2, IL-1ra, IL-8, and VEGF (p < 0.16). buff.ly/UUQHdkh
https://www.sciencedirect.com/science/article/abs/pii/S0049017226001563?via%3Dihub
buff.ly
September 21, 2026 at 8:50 PM
CLOAK study: 3 mos DBRPCT of Colchicine vs PBO (no NSAID) in 120 symptomatic KOA (KL gr 2/3) shows no benefit in VAS pain index knee after 3 mos. (but COL pts had signif change in some biomarkers hsCRP, β-NGF (p < 0.05); PGE2, IL-1ra, IL-8, and VEGF (p < 0.16). buff.ly/UUQHdkh
Our inflammatory markers aren't normal. hsCRP levels show alarming levels of heart inflammation.
Many #LongCOVID patients experience anemia and iron dysregulation. A1c levels are often elevated.
Clinicians need to order the tests that highlight the dangerous of post-COVID impacts.
#medsky
Many #LongCOVID patients experience anemia and iron dysregulation. A1c levels are often elevated.
Clinicians need to order the tests that highlight the dangerous of post-COVID impacts.
#medsky
September 18, 2026 at 2:31 PM
Our inflammatory markers aren't normal. hsCRP levels show alarming levels of heart inflammation.
Many #LongCOVID patients experience anemia and iron dysregulation. A1c levels are often elevated.
Clinicians need to order the tests that highlight the dangerous of post-COVID impacts.
#medsky
Many #LongCOVID patients experience anemia and iron dysregulation. A1c levels are often elevated.
Clinicians need to order the tests that highlight the dangerous of post-COVID impacts.
#medsky
【2型DM例における軽度炎症とCV転帰/EJPC】Sep.16
デンマーク、2型DMと近時診断 [中央値0.9年] のCV1次予防7,630例 [中央値60歳] 解析——
・9年間MACEの部分分布HRは、観察開始時IL-6 1log標準偏差高値
に伴い1.16の有意高値。
・hsCRPでも1.16 [有意] 。
抄録🔗 x.gd/ldgNQ
デンマーク、2型DMと近時診断 [中央値0.9年] のCV1次予防7,630例 [中央値60歳] 解析——
・9年間MACEの部分分布HRは、観察開始時IL-6 1log標準偏差高値
に伴い1.16の有意高値。
・hsCRPでも1.16 [有意] 。
抄録🔗 x.gd/ldgNQ
Low-grade inflammation predicts major cardiovascular events and mortality in recently diagnosed type 2 diabetes: A Danish nationwide cohort study
AbstractAims. This study aimed to investigate the prospective associations of interleukin-6 (IL-6), tumour necrosis factor-α (TNF-α), and high-sensitivity
x.gd
September 17, 2026 at 10:46 PM
【2型DM例における軽度炎症とCV転帰/EJPC】Sep.16
デンマーク、2型DMと近時診断 [中央値0.9年] のCV1次予防7,630例 [中央値60歳] 解析——
・9年間MACEの部分分布HRは、観察開始時IL-6 1log標準偏差高値
に伴い1.16の有意高値。
・hsCRPでも1.16 [有意] 。
抄録🔗 x.gd/ldgNQ
デンマーク、2型DMと近時診断 [中央値0.9年] のCV1次予防7,630例 [中央値60歳] 解析——
・9年間MACEの部分分布HRは、観察開始時IL-6 1log標準偏差高値
に伴い1.16の有意高値。
・hsCRPでも1.16 [有意] 。
抄録🔗 x.gd/ldgNQ
What does low-grade inflammation have to do with biological age? hs-CRP and homocysteine are small lab signals, but chronically higher readings often travel with vascular stress, metabolic strain, and slower recovery.
#hscrp #applewatch
#hscrp #applewatch
September 12, 2026 at 1:43 PM
What does low-grade inflammation have to do with biological age? hs-CRP and homocysteine are small lab signals, but chronically higher readings often travel with vascular stress, metabolic strain, and slower recovery.
#hscrp #applewatch
#hscrp #applewatch
Testosterone? Sure.
But what about hsCRP? A1c? ApoB?
The longevity biomarkers most people aren’t even checking.
We are.
https://longevity.direct
But what about hsCRP? A1c? ApoB?
The longevity biomarkers most people aren’t even checking.
We are.
https://longevity.direct
September 9, 2026 at 4:15 PM
Testosterone? Sure.
But what about hsCRP? A1c? ApoB?
The longevity biomarkers most people aren’t even checking.
We are.
https://longevity.direct
But what about hsCRP? A1c? ApoB?
The longevity biomarkers most people aren’t even checking.
We are.
https://longevity.direct
💉 #pharma
Novo's #ziltivekimab cut the inflammation marker 88% in phase 2. That is why it went into a 6,300-patient phase 3.
Heart attacks, strokes and CV deaths: 0.99. No change at all.
midgardfinance.com/companies/NOVO-B.CO/
🇩🇰 #$NOVO
Novo's #ziltivekimab cut the inflammation marker 88% in phase 2. That is why it went into a 6,300-patient phase 3.
Heart attacks, strokes and CV deaths: 0.99. No change at all.
midgardfinance.com/companies/NOVO-B.CO/
🇩🇰 #$NOVO
September 6, 2026 at 7:00 AM
💉 #pharma
Novo's #ziltivekimab cut the inflammation marker 88% in phase 2. That is why it went into a 6,300-patient phase 3.
Heart attacks, strokes and CV deaths: 0.99. No change at all.
midgardfinance.com/companies/NOVO-B.CO/
🇩🇰 #$NOVO
Novo's #ziltivekimab cut the inflammation marker 88% in phase 2. That is why it went into a 6,300-patient phase 3.
Heart attacks, strokes and CV deaths: 0.99. No change at all.
midgardfinance.com/companies/NOVO-B.CO/
🇩🇰 #$NOVO
【肥満2型DM例CVリスク評価の炎症指標はhsCRPよりもIL-6？/JACC HF】Sep.03
過体重・肥満合併2型DM対象RCTデータ解析——
・試験開始時 hs-CRP濃度 [中央値 2.07 pg/mL]は諸因子補正後、
その後のASCVDやHFリスクと相関認めず [1,902例解析]。
・一方、IL-6高値でHF発症リスクも高。特にCV1じ予防例 [1.507
例解析]。
抄録🔗 x.gd/SrzRh
過体重・肥満合併2型DM対象RCTデータ解析——
・試験開始時 hs-CRP濃度 [中央値 2.07 pg/mL]は諸因子補正後、
その後のASCVDやHFリスクと相関認めず [1,902例解析]。
・一方、IL-6高値でHF発症リスクも高。特にCV1じ予防例 [1.507
例解析]。
抄録🔗 x.gd/SrzRh
Residual Inflammatory Risk of Heart Failure and Atherosclerotic CVD in Diabetes: Look AHEAD Ancillary Study
x.gd
September 3, 2026 at 11:38 PM
【肥満2型DM例CVリスク評価の炎症指標はhsCRPよりもIL-6？/JACC HF】Sep.03
過体重・肥満合併2型DM対象RCTデータ解析——
・試験開始時 hs-CRP濃度 [中央値 2.07 pg/mL]は諸因子補正後、
その後のASCVDやHFリスクと相関認めず [1,902例解析]。
・一方、IL-6高値でHF発症リスクも高。特にCV1じ予防例 [1.507
例解析]。
抄録🔗 x.gd/SrzRh
過体重・肥満合併2型DM対象RCTデータ解析——
・試験開始時 hs-CRP濃度 [中央値 2.07 pg/mL]は諸因子補正後、
その後のASCVDやHFリスクと相関認めず [1,902例解析]。
・一方、IL-6高値でHF発症リスクも高。特にCV1じ予防例 [1.507
例解析]。
抄録🔗 x.gd/SrzRh
The one slide I deleted was the anti inflammatory stuff. So dose dependently reduces hsCRP by about 50% (Ph3 showed 60%, Tirz is similar 50-60%)
Also reduced IL-6.
Some benefits are seen in Tirz. More so with triglyceride lowering, less so with ApoB/LDL.
Would be additive CRP reduction w/statin
Also reduced IL-6.
Some benefits are seen in Tirz. More so with triglyceride lowering, less so with ApoB/LDL.
Would be additive CRP reduction w/statin
August 30, 2026 at 4:27 PM
The one slide I deleted was the anti inflammatory stuff. So dose dependently reduces hsCRP by about 50% (Ph3 showed 60%, Tirz is similar 50-60%)
Also reduced IL-6.
Some benefits are seen in Tirz. More so with triglyceride lowering, less so with ApoB/LDL.
Would be additive CRP reduction w/statin
Also reduced IL-6.
Some benefits are seen in Tirz. More so with triglyceride lowering, less so with ApoB/LDL.
Would be additive CRP reduction w/statin
✨ #ESCCongress 2026: Pacibekitug - Anhaltende IL-6-Hemmung bei hohem inflammatorischen Risiko
🔬 Phase-3-Studie: CMR GUIDE
🎙️ Prof. Deepak Bhatt präsentierte die Daten.
🔍 Prof. Dennis Wolf ordnet die Ergebnisse ein.
➡️ herzmedizin.de/fuer-aerzte-...
#DGK #Kardiologie #CardioSky
🔬 Phase-3-Studie: CMR GUIDE
🎙️ Prof. Deepak Bhatt präsentierte die Daten.
🔍 Prof. Dennis Wolf ordnet die Ergebnisse ein.
➡️ herzmedizin.de/fuer-aerzte-...
#DGK #Kardiologie #CardioSky
TRANQUILITY | ESC Congress 2026
ESC 2026 | TRANQUILITY: Pacibekitug vs. Placebo bei erhöhten hsCRP-Werten und chronischen Nierenerkrankungen. Von Prof. D. Wolf.
herzmedizin.de
August 29, 2026 at 2:06 PM
✨ #ESCCongress 2026: Pacibekitug - Anhaltende IL-6-Hemmung bei hohem inflammatorischen Risiko
🔬 Phase-3-Studie: CMR GUIDE
🎙️ Prof. Deepak Bhatt präsentierte die Daten.
🔍 Prof. Dennis Wolf ordnet die Ergebnisse ein.
➡️ herzmedizin.de/fuer-aerzte-...
#DGK #Kardiologie #CardioSky
🔬 Phase-3-Studie: CMR GUIDE
🎙️ Prof. Deepak Bhatt präsentierte die Daten.
🔍 Prof. Dennis Wolf ordnet die Ergebnisse ein.
➡️ herzmedizin.de/fuer-aerzte-...
#DGK #Kardiologie #CardioSky
Association of the hsCRP- triglyceride-glucose index (CTI) with early infarct growth rate in acute ischemic stroke due to large artery occlusion
Frontiers
www.frontiersin.org/journals/agi...
Frontiers
www.frontiersin.org/journals/agi...
Frontiers | Association of the hsCRP- triglyceride-glucose index (CTI) with early infarct growth rate in acute ischemic stroke due to large artery occlusion
BackgroundRapid infarct growth in acute ischemic stroke (AIS) due to large artery occlusion (LAO) is associated with poor clinical outcomes despite successfu...
www.frontiersin.org
August 28, 2026 at 6:49 AM
Association of the hsCRP- triglyceride-glucose index (CTI) with early infarct growth rate in acute ischemic stroke due to large artery occlusion
Frontiers
www.frontiersin.org/journals/agi...
Frontiers
www.frontiersin.org/journals/agi...
Semaglutide isn’t just about weight loss - it may also reduce inflammation linked to heart risk, according to a major study of 17,000+ adults. 🫀🧪 www.news-medical.net/news/2026082... #Semaglutide #HeartHealth @americanheart.bsky.social
Semaglutide’s heart benefits may partly involve reduced inflammation
A prespecified analysis of 17,604 SELECT participants found that higher baseline hsCRP was associated with greater risks of major cardiovascular events and death in people with overweight or obesity a...
www.news-medical.net
August 24, 2026 at 6:29 AM
Semaglutide isn’t just about weight loss - it may also reduce inflammation linked to heart risk, according to a major study of 17,000+ adults. 🫀🧪 www.news-medical.net/news/2026082... #Semaglutide #HeartHealth @americanheart.bsky.social
【軽度炎症遷延で高血圧発症リスクも高？/EJPC】Aug.18
米国、高血圧診断歴のない女性医療従事者20,224名データ解析——
・最長31年観察で70%が高血圧発症。
・観察開始時hsCRP「最高」五分位群では「最低」群に比べ、
HTN発症HRが1.33の有意高値。
・hsCRPの影響が著明なのは「観察開始後20年」まで。
抄録🔗 x.gd/7mu0Z
米国、高血圧診断歴のない女性医療従事者20,224名データ解析——
・最長31年観察で70%が高血圧発症。
・観察開始時hsCRP「最高」五分位群では「最低」群に比べ、
HTN発症HRが1.33の有意高値。
・hsCRPの影響が著明なのは「観察開始後20年」まで。
抄録🔗 x.gd/7mu0Z
Inflammation and the Long-Term Incidence of Hypertension in Women
AbstractAims. Chronic inflammation associates with prevalent and short-term incident hypertension. The aim of this study is to determine whether baseline h
x.gd
August 19, 2026 at 10:41 PM
【軽度炎症遷延で高血圧発症リスクも高？/EJPC】Aug.18
米国、高血圧診断歴のない女性医療従事者20,224名データ解析——
・最長31年観察で70%が高血圧発症。
・観察開始時hsCRP「最高」五分位群では「最低」群に比べ、
HTN発症HRが1.33の有意高値。
・hsCRPの影響が著明なのは「観察開始後20年」まで。
抄録🔗 x.gd/7mu0Z
米国、高血圧診断歴のない女性医療従事者20,224名データ解析——
・最長31年観察で70%が高血圧発症。
・観察開始時hsCRP「最高」五分位群では「最低」群に比べ、
HTN発症HRが1.33の有意高値。
・hsCRPの影響が著明なのは「観察開始後20年」まで。
抄録🔗 x.gd/7mu0Z
【GLP-1RAで過体重・肥満例のhsCRP著明低下：RCT “SELECT”事前設定追加解析/Circ】Aug.18
ASCVD既往のある「BMI≧27」17,604例ランダム化データ解析——
・GLP-1RA群のhsCRPは試験開始1年後には62%まで有意低下。
104週まで維持。
・プラセボ群ではほぼ不変。
・GLP-1RA群におけるhsCRP低下率は、試験終了時の体重減少率
が5％以上であれば、減量率の大小間で有意差なし。
全文🔗 x.gd/fnWTt
ASCVD既往のある「BMI≧27」17,604例ランダム化データ解析——
・GLP-1RA群のhsCRPは試験開始1年後には62%まで有意低下。
104週まで維持。
・プラセボ群ではほぼ不変。
・GLP-1RA群におけるhsCRP低下率は、試験終了時の体重減少率
が5％以上であれば、減量率の大小間で有意差なし。
全文🔗 x.gd/fnWTt
August 19, 2026 at 1:12 AM
【GLP-1RAで過体重・肥満例のhsCRP著明低下：RCT “SELECT”事前設定追加解析/Circ】Aug.18
ASCVD既往のある「BMI≧27」17,604例ランダム化データ解析——
・GLP-1RA群のhsCRPは試験開始1年後には62%まで有意低下。
104週まで維持。
・プラセボ群ではほぼ不変。
・GLP-1RA群におけるhsCRP低下率は、試験終了時の体重減少率
が5％以上であれば、減量率の大小間で有意差なし。
全文🔗 x.gd/fnWTt
ASCVD既往のある「BMI≧27」17,604例ランダム化データ解析——
・GLP-1RA群のhsCRPは試験開始1年後には62%まで有意低下。
104週まで維持。
・プラセボ群ではほぼ不変。
・GLP-1RA群におけるhsCRP低下率は、試験終了時の体重減少率
が5％以上であれば、減量率の大小間で有意差なし。
全文🔗 x.gd/fnWTt
There’s a simple blood test that can reveal a key marker of inflammation: hsCRP.
For APOE4 carriers, understanding inflammation may be especially important for brain health.
Watch -
For APOE4 carriers, understanding inflammation may be especially important for brain health.
Watch -
APOE4? Don't Miss This $10 Blood Test
APOE4 carriers: have you checked your hsCRP?hsCRP measures high-s...
youtube.com
August 18, 2026 at 6:04 PM
There’s a simple blood test that can reveal a key marker of inflammation: hsCRP.
For APOE4 carriers, understanding inflammation may be especially important for brain health.
Watch -
For APOE4 carriers, understanding inflammation may be especially important for brain health.
Watch -
Novo’s ziltivekimab failure challenges the “lower hsCRP, improve outcomes” thesis – DLT data point to NLRP3 and senescent-cell biology next.
Link as first comment.
#longevity #geroscience #ziltivekimab #inflammation #senescence
Link as first comment.
#longevity #geroscience #ziltivekimab #inflammation #senescence
August 17, 2026 at 11:27 AM
Novo’s ziltivekimab failure challenges the “lower hsCRP, improve outcomes” thesis – DLT data point to NLRP3 and senescent-cell biology next.
Link as first comment.
#longevity #geroscience #ziltivekimab #inflammation #senescence
Link as first comment.
#longevity #geroscience #ziltivekimab #inflammation #senescence
The IL-6 inhibitor ziltivekimab failed to reduce cardiovascular events in the ZEUS trial by Novo, which enrolled over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and hsCRP ≥2 mg/L. The HR for major cardiovascular events was a disappointing 0.99.
August 16, 2026 at 11:12 AM
The IL-6 inhibitor ziltivekimab failed to reduce cardiovascular events in the ZEUS trial by Novo, which enrolled over 6,300 patients with atherosclerotic cardiovascular disease, chronic kidney disease, and hsCRP ≥2 mg/L. The HR for major cardiovascular events was a disappointing 0.99.
Think of hsCRP as a smoke alarm for chronic inflammation.
Ignore it and you miss the fire.
Track it and act.
https://longevity.direct
Ignore it and you miss the fire.
Track it and act.
https://longevity.direct
August 12, 2026 at 6:30 PM
Think of hsCRP as a smoke alarm for chronic inflammation.
Ignore it and you miss the fire.
Track it and act.
https://longevity.direct
Ignore it and you miss the fire.
Track it and act.
https://longevity.direct
Novo Nordisk's clinical trial for Ziltivekimab, an antibody targeting pro-inflammatory cytokine IL-6, failed 👀
Interestingly, both IL-6 and hsCRP fell with treatment, suggesting an anti-inflammatory effect, yet this did not translate into fewer cardiovascular events.
Interestingly, both IL-6 and hsCRP fell with treatment, suggesting an anti-inflammatory effect, yet this did not translate into fewer cardiovascular events.
August 11, 2026 at 2:59 PM
Novo Nordisk's clinical trial for Ziltivekimab, an antibody targeting pro-inflammatory cytokine IL-6, failed 👀
Interestingly, both IL-6 and hsCRP fell with treatment, suggesting an anti-inflammatory effect, yet this did not translate into fewer cardiovascular events.
Interestingly, both IL-6 and hsCRP fell with treatment, suggesting an anti-inflammatory effect, yet this did not translate into fewer cardiovascular events.